Amphastar Pharmaceuticals Cash Flow Statement
NASDAQ: AMPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amphastar Pharmaceuticals free cash flow
In fiscal 2025, Amphastar Pharmaceuticals generated $156.1 million of operating cash flow and spent $34.9 million on capital expenditures. That left free cash flow of $121.2 million, a free-cash-flow margin of 16.8% of revenue. Free cash flow was down 29.7% from the prior year's $172.3 million.
Amphastar Pharmaceuticals returned $75.6 million to shareholders through share repurchases, equal to 62% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Amphastar Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 98.09M | 159.52M | 137.54M | 91.39M | 63.30M | 1.10M | 46.51M | -6.66M | 3.65M | 9.82M |
| Net Income growth (YoY) | -38.51% | +15.98% | +50.51% | +44.37% | +5670.37% | -97.64% | — | -282.62% | -62.86% | — |
| Depreciation & Amortization | 31.65M | 28.25M | 25.74M | 12.60M | 10.22M | 9.03M | 7.06M | 6.05M | 6.42M | 12.16M |
| Stock-Based Compensation | 27.28M | 24.37M | 20.24M | 17.86M | 18.69M | 20.50M | 17.30M | 16.68M | 17.09M | 15.12M |
| Change in Working Capital | -35.52M | -17.63M | -17.30M | -24.47M | -7.10M | 15.87M | -49.73M | 8.26M | 12.42M | -2.76M |
| Operating Cash Flow | 156.12M | 213.39M | 183.50M | 89.18M | 97.99M | 57.27M | 41.76M | 38.19M | 39.21M | 38.56M |
| Capital Expenditures | -34.88M | -41.04M | -38.17M | -24.03M | -27.46M | -33.85M | -41.55M | -46.81M | -35.10M | -21.38M |
| Investing Cash Flow | -70.33M | -124.93M | -649.12M | -32.78M | -28.67M | -36.41M | -50.53M | -42.18M | -36.89M | -39.50M |
| Share Repurchases | -75.59M | -85.46M | -58.14M | -39.91M | -28.87M | -24.43M | -22.29M | -25.05M | -30.75M | -9.91M |
| Debt Issued | — | — | 845.00M | — | 70.00M | 6.28M | 3.57M | 8.43M | 18.98M | 10.20M |
| Debt Repaid | -223.00K | -8.26M | -318.66M | -1.78M | -36.74M | -8.40M | -6.43M | -5.71M | -9.71M | -14.65M |
| Financing Cash Flow | -67.42M | -80.95M | 454.09M | -26.44M | -37.02M | -2.25M | -3.78M | 25.01M | -7.72M | 7.14M |
| Net Change in Cash | 18.57M | 7.31M | -11.80M | 29.75M | 32.08M | 18.96M | -12.65M | 20.74M | -4.89M | 6.28M |
| Free Cash Flow | 121.23M | 172.34M | 145.34M | 65.15M | 70.54M | 23.41M | 207.00K | -8.62M | 4.11M | 17.18M |
This table shows 10 annual periods of Amphastar Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMPH's reporting calendar. What is a cash flow statement?